25 May 2001 -
The Henkel Group has acquired a minority interest in Natural Implant, a biotechnology company established two years ago in Lyon, France.
After Vermicon, Natural Implant is the second biotechnology company in which Henkel has taken a minority shareholding. Natural Implant has expertise in tissue engineering, i.e. the possibility of growing complex three dimensional human tissues such as skin. "This investment provides an excellent opportunity to utilize Natural Implant's technology for our own research," comments Dr. Wolfgang Gawrisch, Corporate Vice President Research/Technology at Henkel. "Natural Implant's competence in tissue engineering further enhances our biotechnology activities." Henkel's intention is to reinforce its activities in biotechnology through cell culturing in order to make consumer products even more effective and safer. Beyond this, Natural Implant's competence opens up new perspectives for product innovations in important markets. The commitment to biotechnology and positioning as a competent partner and investor is a strategic decision pro innovation and growth.
Top
Print version
PDF version
Send article
RSS feed